

CORRECTION TO “TWO NEW POLYMORPHISMS OF THE *FMO3* GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES”

In the above article [Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) *Drug Metab Dispos* **31**:854–860], the following errors should be corrected.

On page 856: The sentence “The His¹³²-*FMO3* variant (i.e., change of an aspartic acid to a histidine) resulted from a G to T transition at nucleotide position 394.” should be corrected to: “The His¹³²-*FMO3* variant (i.e., change of an aspartic acid to a histidine) resulted from a G to C transition at nucleotide position 394.”

On page 856: The sentence “The Pro³⁶⁰-*FMO3* variant (i.e., change of a leucine to a proline) resulted from a T to A transition at nucleotide position 1079.” should be corrected to: “The Pro³⁶⁰-*FMO3* variant (i.e., change of a leucine to a proline) resulted from a T to C transition at nucleotide position 1079.”

On page 857: In Table 2, first row: “H132(C→G K158(A→G M257(A→G) G308(G→A) P360(C→T)” should be corrected to: “H132(G→C K158(A→G M257(G→A) G308(A→G) P360(T→C).”

We apologize for any confusion and inconvenience caused by these errors.